World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Acurion Closes Oversubscribed $4.3 Million Seed Round to Advance AI-Driven Precision Oncology Platform

Cision PR Newswire by Cision PR Newswire
April 2, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Funding led by TK Partners supports further clinical validation, regulatory preparation, and commercialization of OncoGaze™

SAN DIEGO, April 2, 2026 /PRNewswire/ — Acurion, a precision oncology technology company advancing AI-driven cancer biomarker detection through its OncoGaze™ platform, today announced the closing of its oversubscribed seed financing round, raising $4.3 million against a $4 million target.  


Acurion
Immediate Precision, Optimal Care. (PRNewsfoto/Acurion)

The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research and the Asian Fund for Cancer Research, Bootstrap Ventures, and institutional investors, impact funds, and healthcare executives.  

The financing will further support clinical validation, platform development, regulatory preparation, and commercialization as Acurion advances OncoGaze™ toward broader clinical and research adoption.  

“This financing represents strong validation of our technology and mission,” said Rick Fultz, CEO of Acurion. “The future of precision oncology depends on making advanced biomarker detection accessible, scalable, and instantly actionable in real-world clinical settings. This investment helps us accelerate development and bring our technology closer to meaningful impact for cancer patients.”  

“Acurion stood out immediately — tackling a global problem with a strong technical edge, a standout team, and a clear approach to execution,” said TK & Partners’ Chairman, Tomas Koch.  

“AI has the potential to reshape how we detect and act on cancer biomarkers,” said Carey Ng, Ph.D., Managing Partner at Mesa Verde Venture Partners. “What stood out to us about Acurion is their ability to translate complex science into a solution that fits directly into existing clinical workflows. This is the kind of innovation that can expand access to precision oncology at scale.”  

Acurion’s technology builds on foundational work by co-founder and Chief Scientific Officer Ludmil Alexandrov, Ph.D., Professor of Cellular and Molecular Medicine at UC San Diego, whose work on mutational signatures has reshaped understanding of cancer origins and treatment response.  

The company has achieved significant scientific and industry milestones, including publications in leading oncology and scientific journals, expanding collaborations with clinical partners, and engaging industry leaders.  

“We’re moving quickly from validation to deployment,” Fultz added. “Our focus now is executing key clinical and regulatory milestones and getting this into the hands of physicians who can use it.”  

The company expects to announce additional clinical collaborations and regulatory progress in the coming months.

About Acurion  
Acurion is a San Diego-based precision oncology company developing AI-powered image analysis tools for biomarker detection, uncovering clinically actionable insights from conventional pathology images. Unlike genomic testing approaches often requiring additional tissue or specialized molecular testing, Acurion’s OncoGaze™ platform extracts biomarker insights from routine pathology slides prepared during standard clinical care, enabling an instantaneous, scalable and accessible approach to precision medicine.  

Despite major advances in targeted therapies, many cancer patients either lack access to biomarker testing or face life-threatening testing delays. Acurion aims to expand access to precision oncology by improving biomarker detection and treatment selection across multiple advanced cancer types.  

For more information visit:
www.acurionhealth.com  

Media Contact 
Catherine Eng
ceng@acurionhealth.com
818-795-7184  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/acurion-closes-oversubscribed-4-3-million-seed-round-to-advance-ai-driven-precision-oncology-platform-302733064.html

SOURCE Acurion

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Thunes and PayerMax Deepen Strategic Collaboration to Enhance Global Payout Capabilities

    0 shares
    Share 0 Tweet 0
  • Linux Foundation Announces the Open Financial Trust Alliance to Strengthen Coordinated Protection Against Fraud, Scams and Financial Crime

    0 shares
    Share 0 Tweet 0
  • DEFSEC TECHNOLOGIES INC. COMMENTS ON NASDAQ NOTIFICATION REGARDING BID PRICE DEFICIENCY AND PROACTIVE STEPS ALREADY TAKEN TO REGAIN AND MAINTAIN COMPLIANCE

    0 shares
    Share 0 Tweet 0
  • PingPong Hits $300 Billion in Annualised Transaction Volume as APAC Surges, and Launches “Currentz” for Banks

    0 shares
    Share 0 Tweet 0
  • Charter Announces Pricing Terms of Tender Offers for Eight Series of Notes

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler